Guangdong Xinyaguang Cable
001382
Haimo Technologies Group Corp.
300084
Shaoyang Victor Hydraulics
301079
KLT
831689
Qingdao Tianneng Heavy Industries
300569
CN Stock MarketDetailed Quotes
688062 Mabwell
- 17.82
- -1.05-5.56%
Market Closed Mar 21 15:00 CST
7.12BMarket Cap-6.63P/E (TTM)
18.86High17.61Low65.65KlotVolume18.80Open18.87Pre Close118.26MTurnover3.22%Turnover RatioLossP/E (Static)399.60MShares36.9952wk High3.71P/B3.64BFloat Cap15.3652wk Low22.64Limit Up204.17MShs Float37.00Historical High15.10Limit Down6.62%Amplitude12.96Historical Low--Dividend TTM18.01Avg Price40.53KlotAsk--Div YieldTTM100Lot Size22.70KlotBid
Mabwell News
Maiwei Biotech Investor Relations Activity Record List (March 1, 2025)
Maiwei Biotech Investor Relations Activity Record List (February 01, 2025)
Maiwei Biotech: Maiwei Biotech 2024 Annual Performance Report Announcement
Maiwei Biotech 2024 Annual Results Report Announcement
Maiwei Biotech Investor Relations Activity Record List (January 1, 2025)
Maiwei Biotech: Maiwei Biotech\'s announcement on continuing to use some temporarily idle funds raised for cash management
Maiwei Biotech: Announcement of Resolutions of the 15th Meeting of the 2nd Supervisory Board of Maiwei Biotech
Maiwei Biology: Opinions of Haitong Securities Co., Ltd. on the continued use of some temporarily idle funds raised by Maiwei (Shanghai) Biotechnology Co., Ltd. for cash management
Haitong Securities Co., Ltd.\'s verification opinion on Maiwei (Shanghai) Biotechnology Co., Ltd. continuing to use some temporarily idle funds raised for cash management
Maiwei Biotech\'s announcement on continuing to use some temporarily idle funds raised for cash management
Announcement of Resolutions of the 15th Meeting of the 2nd Supervisory Board of Maiwei Biotech
Maiwei Biotech 2024 Annual Results Forecast
Maiwei Biotech: Maiwei Biotech voluntarily disclosed the announcement that 9MW2821 combined with treprimab was included in the public list of breakthrough treatment varieties for first-line treatment of urothelial cancer
Maiwei Biotech voluntarily disclosed an announcement on the inclusion of 9MW2821 and treprilizumab in the first-line treatment of urothelial cancer in the public list of breakthrough treatment varieties
Maiwei Biotech: Announcement on the submission of an application for the issuance and listing of H shares to the Hong Kong Stock Exchange and publication of application materials
Maiwei Biotech: Maiwei Biotech\'s announcement on opening a special fund raising account and signing a tripartite supervisory agreement for fund raising special account storage
Announcement of Maiwei Biotech on opening a special fund-raising account and signing a tripartite supervisory agreement for fund-raising special account storage
Announcement of Maiwei Biotech\'s submission of an application for the issuance and listing of H shares to the Hong Kong Stock Exchange and publication of application materials
Maiwei Biotech Investor Relations Activity Record List (December 1, 2024)
Legal Opinion of Beijing Zhide (Shanghai) Law Firm on the 2024 Fourth Extraordinary General Meeting of Shareholders of Maiwei (Shanghai) Biotechnology Co., Ltd.
